Moomoo AI 已提取核心訊息
On January 18, 2024, Incannex Healthcare Inc., a pharmaceutical company specializing in medicinal cannabinoid and psychedelic medicine therapies, announced the completion of dosing and treatment protocols for all participants in its PsiGAD-1 clinical trial. The trial, which took place at Monash University in Melbourne, Australia, involved 72 patients and is part of a Phase 2 study to evaluate the company's psilocybin treatment program for generalized anxiety disorder (GAD). The study aims to determine the efficacy of a 7-week psilocybin-assisted psychotherapy program compared to an active placebo. With safety and tolerability assessed, the trial also looks at secondary objectives of efficacy and quality of life. The interim analysis suggested a high probability of significant benefit for the psilocybin treatment over the placebo. Incannex is preparing an FDA IND application following the anticipated Q1 2024 topline results. Additionally, a documentary covering the Monash Clinical Psychedelic Lab and the PsiGAD research program is set to be released by the SBS television network in late February 2024.
On January 18, 2024, Incannex Healthcare Inc., a pharmaceutical company specializing in medicinal cannabinoid and psychedelic medicine therapies, announced the completion of dosing and treatment protocols for all participants in its PsiGAD-1 clinical trial. The trial, which took place at Monash University in Melbourne, Australia, involved 72 patients and is part of a Phase 2 study to evaluate the company's psilocybin treatment program for generalized anxiety disorder (GAD). The study aims to determine the efficacy of a 7-week psilocybin-assisted psychotherapy program compared to an active placebo. With safety and tolerability assessed, the trial also looks at secondary objectives of efficacy and quality of life. The interim analysis suggested a high probability of significant benefit for the psilocybin treatment over the placebo. Incannex is preparing an FDA IND application following the anticipated Q1 2024 topline results. Additionally, a documentary covering the Monash Clinical Psychedelic Lab and the PsiGAD research program is set to be released by the SBS television network in late February 2024.
2024年1月18日，專門從事藥用大麻素和迷幻藥物療法的製藥公司Incannex Healthcare Inc. 宣佈完成了其psIGAD-1臨床試驗所有參與者的劑量和治療方案。該試驗在澳大利亞墨爾本的莫納什大學進行，涉及72名患者，是評估該公司廣泛性焦慮症（GAD）迷幻藥治療計劃的2期研究的一部分。該研究旨在確定爲期7周的迷幻藥輔助心理治療計劃與活性安慰劑相比的療效。通過評估安全性和耐受性，該試驗還着眼於療效和生活質量的次要目標。中期分析表明，與安慰劑相比，迷幻藥治療很有可能產生顯著的益處。根據預期的2024年第一季度業績，Incannex正在準備FDA的IND申請。此外，SBS電視網定於2024年2月下旬發佈一部報道莫納什臨床迷幻實驗室和PSIGad研究計劃的紀錄片。
2024年1月18日，專門從事藥用大麻素和迷幻藥物療法的製藥公司Incannex Healthcare Inc. 宣佈完成了其psIGAD-1臨床試驗所有參與者的劑量和治療方案。該試驗在澳大利亞墨爾本的莫納什大學進行，涉及72名患者，是評估該公司廣泛性焦慮症（GAD）迷幻藥治療計劃的2期研究的一部分。該研究旨在確定爲期7周的迷幻藥輔助心理治療計劃與活性安慰劑相比的療效。通過評估安全性和耐受性，該試驗還着眼於療效和生活質量的次要目標。中期分析表明，與安慰劑相比，迷幻藥治療很有可能產生顯著的益處。根據預期的2024年第一季度業績，Incannex正在準備FDA的IND申請。此外，SBS電視網定於2024年2月下旬發佈一部報道莫納什臨床迷幻實驗室和PSIGad研究計劃的紀錄片。
有用
沒用